<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448747</url>
  </required_header>
  <id_info>
    <org_study_id>AEZS 130 047</org_study_id>
    <nct_id>NCT00448747</nct_id>
  </id_info>
  <brief_title>Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.</brief_title>
  <official_title>A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly Ardana (ARD)-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of growth hormone deficiency (GHD) in adults is established by laboratory
      testing in patients with an appropriate clinical history of hypothalamic pituitary disease.
      Two tests that are considered to be gold standard tests for the diagnosis of GHD are the
      insulin tolerance test (ITT) and growth hormone releasing hormone (GHRH) combined with
      L-arginine (L-ARG). However, these tests are either bothersome (given intravenously) to the
      patient or are linked with side effects. Therefore, an orally available compound like
      AEZS-130 (formerly ARD-07), if demonstrated to be safe and providing adequate sensitivity and
      specificity could be a welcome alternative and/or complement to the current available tests.

      The intent was to recruit 40 adult GHD (AGHD) patients and 40 healthy control subjects into
      this trial, but the original sponsor (Ardana Biosciences Ltd.) discontinued the study for
      financial reasons before this was completed. At the time of withdrawal of GHRH from the
      market in 2008, 42 AGHD patients and 10 normal controls had completed the study at 9 US
      sites. This study reactivated to complete the remaining 30 matched control subjects.

      Additionally upon agreement with the FDA in a Special Protocol Assessment (SPA), 10
      additional adult growth hormone deficient and their matched control were planned to be
      enrolled into this trial for a total treated population of approximatively 100 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty control subjects (i.e., without AGHD) were matched to the 30 AGHD patients who were
      not previously matched. Matching was based upon gender, age, BMI, and estrogen status for
      females. They received one oral dose of AEZS-130 followed by serial blood draws for growth
      hormone (GH), insulin-like growth factor 1 (IGF-1) and pharmacokinetic (PK) determinations.
      There was no cross over due to the unavailability of GHRH (Geref) in the United States. Under
      Amendment #4 to this protocol, 10 additional AGHD subjects were to be enrolled and matched as
      described above.

      Furthermore, the objective of the study was changed to delete comparison with L-ARG + GHRH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Multi-center, randomized, open-label, cross-over trial to compare AEZS-130 to an established GH stimulation test, L-ARG+GHRH, in the diagnosis of GH deficiency and in terms of safety. Following Amendment no. 3 (version 27 May 2010) , no cross-over was performed anymore due to unavailability of L-ARG+GHRH with resulting single arm testing of AEZS-130. Thus, two treatment arms were applicable only as long as GHRH as substance was available.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations</measure>
    <time_frame>GH sampling: pre-dose and 30, 45, 60, 75, 90, 120, 150 min post-dose</time_frame>
    <description>The primary endpoint for each individual is the peak GH concentration following AEZS-130 (macimorelin) administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Insulin-Like Growth Factor (IGF)-1 Concentration Following Treatment</measure>
    <time_frame>15 min. before macimorelin administration and at 150 min after macimorelin administration</time_frame>
    <description>Descriptive summaries for IGF-1 and correlation with GH concentrations based on macimorelin treatment. Mean IGF-1 values taken pre- and post- macimorelin administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification and Regression Tree (CART) Analysis of Peak Growth Hormone (GH) Following Macimorelin Administration</measure>
    <time_frame>GH sampling: pre-dose and 30, 45, 60, 75, 90, 120, 150 min post-dose</time_frame>
    <description>The CART Analysis for macimorelin estimated: a) a macimorelin cut-point that minimized the misclassification of AGHD patients and healthy control subjects; b) an optimal decision tree for macimorelin that incorporated age, sex and BMI.
Sensitivity (correct identification of AGHD cases) and specificity (correct identification of control subjects) for macimorelin was summarized for age, gender, BMI and estrogen status subgroups containing n &gt; 10.
At least 8 of the 10 newly enrolled AGHD patients should have been correctly classified for a protocol pre-specified threshold of Peak GH concentration which was 8.5 (ng/ml).
Software CART Version 6.0 was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Related Adverse Events (AEs)</measure>
    <time_frame>14 days</time_frame>
    <description>Total number of participants with drug related AEs, following macimorelin administration of L-Arginine (ARG) - Growth Hormone Releasing Hormone (GHRH) administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Diagnosis of Adult Growth Hormone Deficiency (AGDH)</condition>
  <arm_group>
    <arm_group_label>AEZS-130 ( formerly ARD-07)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-ARG+GHRH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEZS-130 (formerly ARD-07)</intervention_name>
    <description>A single oral administration of AEZS-130 as Growth Hormone Stimulation Test</description>
    <arm_group_label>AEZS-130 ( formerly ARD-07)</arm_group_label>
    <other_name>Test 1</other_name>
    <other_name>Macimorelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-ARG+GHRH</intervention_name>
    <description>A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test</description>
    <arm_group_label>L-ARG+GHRH</arm_group_label>
    <other_name>Test Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion for Matched Control Subjects:

          -  Undergone normal growth and development

          -  Normal serum prolactin (PRL) concentrations

          -  Females should have a history of regular, age-appropriate menses

          -  Males should have normal serum testosterone concentrations

          -  Matched GHD subject already enrolled in study; matched in terms of sex, age, BMI and
             Estrogen status (women only)

        Exclusion Criteria for Matched Control Subjects:

          -  Inability or unwillingness to comply with study medication

          -  Pregnancy or lactation

          -  Clinically relevant ECG abnormalities (including QT/QTc interval &gt; 450 ms) at any time
             prior to dosing at Visit 2

          -  Treatment with any drugs that might prolong QT/QTc

        Inclusion criteria dor Adult GHD Subjects:

          -  Confirmed GH deficiency with a low IGF-1

          -  3 months of stable treatment for those requiring hormone replacement therapy for
             hormones deficiencies other than GHD

          -  subjects with hypogonadism must be treated with sex steroid therapy, excluding women
             over 50 yr of age

          -  women on estrogen therapy, for whatever reason, must be on stable treatment for ar
             least 3 months prior to study

        Exclusion criteria for Adult GHD Subjects:

          -  Untreated hypothyroidism

          -  Known hypersensitivity to any excipient in study medication

          -  Inability or unwillingness to comply with study procedures

          -  Intracranial lesions stable for less than 12 months

          -  GH therapy within one month of study entry

          -  Clinically significant cardiovascular, or cerebrovascular disease

          -  Current active malignancy other than non-melanoma skin cancer

          -  Renal or hepatic dysfunction (&gt; 3 x ULN liver function enzymes (LFEs) - aspartate
             amino transferase (ASAT); alanine amino transferase (ALAT); gamma-glutamyltransferase
             (GGT) or creatinine &gt; 2x ULN)

          -  Pregnancy or lactation

          -  Active Cushing's disease

          -  Clinically relevant ECG abnormalities (including QT/heart rate corrected QT interval
             (QTc) interval &gt; 450 ms) at any time prior to dosing at Visit 2

          -  Treatment with any drugs that might prolong QT/QTc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly MK Biller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital, Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound HCS University of Washington</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, Cook D, Yuen KC, Bonert V, Dobs A, Molitch ME, Merriam GR. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2013 Jun;98(6):2422-9. doi: 10.1210/jc.2013-1157. Epub 2013 Apr 4.</citation>
    <PMID>23559086</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>March 16, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <results_first_submitted>December 14, 2017</results_first_submitted>
  <results_first_submitted_qc>July 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ghrelin mimetic, growth hormone secretagogue</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To share IPD is not planned as subjects were not informed about this possibility and thus, no related patient consent is available (data protection issue).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 53 AGHD patients and 48 matched control subjects were enrolled at 11 centers across the United States, and all subjects, with the exception of 1 AGHD patient, received macimorelin and completed the study.
In Amendment No. 4, the objective of the study was changed to delete the comparison with L-ARG + GHRH.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AGHD Patients (= Cases)</title>
          <description>All Adult Growth Hormone Deficiency (AGHD) patients enrolled in the study.</description>
        </group>
        <group group_id="P2">
          <title>Matched Controls (= Controls)</title>
          <description>All matched control subjects enrolled in the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Drug Administration</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Second Drug Administration</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received AEZS-130</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received L-ARG-GHRH</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received L-ARG-GHRH and AEZS-130</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population (PPS)</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>collapsed veins</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Saftey Analysis Set. This is including one case (AGHD patient) who did not receive AEZS-130.</population>
      <group_list>
        <group group_id="B1">
          <title>AGHD Patients (= Cases)</title>
          <description>All AGHD patients enrolled in the study.</description>
        </group>
        <group group_id="B2">
          <title>Matched Controls (= Controls)</title>
          <description>All matched control subjects enrolled in the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Lean (&lt;25)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Overweight (&gt;=25 and &lt;30)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Obese (&gt;=30)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Etiology of AGHD</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pituitary Adenoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS tumors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations</title>
        <description>The primary endpoint for each individual is the peak GH concentration following AEZS-130 (macimorelin) administration.</description>
        <time_frame>GH sampling: pre-dose and 30, 45, 60, 75, 90, 120, 150 min post-dose</time_frame>
        <population>PPS = per protocol set: this was considered to be the most appropriate for determination of the diagnostic utility of macimorelin</population>
        <group_list>
          <group group_id="O1">
            <title>Cases/AEZS-130 Administered</title>
            <description>All AGHD patients who were enrolled in the study and following macimorelin administration.</description>
          </group>
          <group group_id="O2">
            <title>Control/AEZS-130 Administered</title>
            <description>All matched control subjects who enrolled in the study and following macimorelin administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations</title>
          <description>The primary endpoint for each individual is the peak GH concentration following AEZS-130 (macimorelin) administration.</description>
          <population>PPS = per protocol set: this was considered to be the most appropriate for determination of the diagnostic utility of macimorelin</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="5.69"/>
                    <measurement group_id="O2" value="17.71" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Summary of ROC Analyses following macimorelin administration.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ROC AUC</param_type>
            <param_value>0.923</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.850</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ROC analysis on peak GH concentrations in response to macimorelin: GH cut point of 2.7 ng/mL.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Sensitivity</non_inferiority_desc>
            <param_type>sensitivity (percent)</param_type>
            <param_value>82</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ROC analysis on peak GH concentrations in response to macimorelin: GH cut point of 2.7 ng/mL.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Specificity</non_inferiority_desc>
            <param_type>Specificity (percent)</param_type>
            <param_value>92</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ROC analysis on peak GH concentrations in response to macimorelin: GH cut point of 2.7 ng/mL.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Misclassification</non_inferiority_desc>
            <param_type>misclassification (percent)</param_type>
            <param_value>13</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Insulin-Like Growth Factor (IGF)-1 Concentration Following Treatment</title>
        <description>Descriptive summaries for IGF-1 and correlation with GH concentrations based on macimorelin treatment. Mean IGF-1 values taken pre- and post- macimorelin administration.</description>
        <time_frame>15 min. before macimorelin administration and at 150 min after macimorelin administration</time_frame>
        <population>Modified Intent-to-treat analysis set used for analysis of mean IGF-1 values taken pre- and post-macimorelin administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Case/AEZS-130 Administered</title>
            <description>All AGHD patients who received macimorelin.</description>
          </group>
          <group group_id="O2">
            <title>Control/AEZS-130 Administered</title>
            <description>All matched control subjects who received macimorelin.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Insulin-Like Growth Factor (IGF)-1 Concentration Following Treatment</title>
          <description>Descriptive summaries for IGF-1 and correlation with GH concentrations based on macimorelin treatment. Mean IGF-1 values taken pre- and post- macimorelin administration.</description>
          <population>Modified Intent-to-treat analysis set used for analysis of mean IGF-1 values taken pre- and post-macimorelin administration.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 min before AEZS-130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" spread="37.29"/>
                    <measurement group_id="O2" value="128.1" spread="52.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 min after AEZS-130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" spread="34.57"/>
                    <measurement group_id="O2" value="125.9" spread="54.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Summary of IGF-1 before and after AEZS-130 administration: post - pre differences</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.57</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.25</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Classification and Regression Tree (CART) Analysis of Peak Growth Hormone (GH) Following Macimorelin Administration</title>
        <description>The CART Analysis for macimorelin estimated: a) a macimorelin cut-point that minimized the misclassification of AGHD patients and healthy control subjects; b) an optimal decision tree for macimorelin that incorporated age, sex and BMI.
Sensitivity (correct identification of AGHD cases) and specificity (correct identification of control subjects) for macimorelin was summarized for age, gender, BMI and estrogen status subgroups containing n &gt; 10.
At least 8 of the 10 newly enrolled AGHD patients should have been correctly classified for a protocol pre-specified threshold of Peak GH concentration which was 8.5 (ng/ml).
Software CART Version 6.0 was used.</description>
        <time_frame>GH sampling: pre-dose and 30, 45, 60, 75, 90, 120, 150 min post-dose</time_frame>
        <population>PPS = per protocol set. Decision tree for sex abandoned. Following Amendment No. 4, no comparison with L-ARG + GHRH was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Peak GH</title>
            <description>CART analysis of Peak GH following macimorelin administration
Case Definition: GH ≤ 2.85 Control Definition: GH &gt; 2.85</description>
          </group>
          <group group_id="O2">
            <title>Peak GH &amp; BMI</title>
            <description>CART analysis of Peak GH following macimorelin &amp; BMI
Case Definition: GH ≤ 2.85 or (2.85 &lt;GH ≤7.15 &amp; BMI ≤37.28) Control Definition: GH &gt;7.15 or (2.85&lt;GH≤7.15 and BMI&gt;37.28)</description>
          </group>
          <group group_id="O3">
            <title>Peak GH &amp; Age</title>
            <description>CART analysis of Peak GH following macimorelin &amp; Age
Case Definition: GH ≤ 2.85 or (2.85 &lt;GH ≤7.15 &amp; age ≤47.5) Control Definition: GH &gt; 7.15 or (2.85 &lt;GH ≤7.15 &amp; age &gt;47.5)</description>
          </group>
          <group group_id="O4">
            <title>Peak GH &amp; BMI &amp; Age</title>
            <description>CART analysis of Peak GH following macimorelin &amp; BMI &amp; Age
Case Definition:
GH≤0.85 or (0.85&lt;GH≤2.85 and BMI&gt;27.94) or (2.85&lt;GH≤7.15 and age ≤47.5)
Control Definition:
GH &gt; 7.15 or (0.85 &lt;GH ≤2.85 &amp; BMI ≤27.94) or (2.85&lt;GH≤7.15 and age &gt;47.5)</description>
          </group>
        </group_list>
        <measure>
          <title>Classification and Regression Tree (CART) Analysis of Peak Growth Hormone (GH) Following Macimorelin Administration</title>
          <description>The CART Analysis for macimorelin estimated: a) a macimorelin cut-point that minimized the misclassification of AGHD patients and healthy control subjects; b) an optimal decision tree for macimorelin that incorporated age, sex and BMI.
Sensitivity (correct identification of AGHD cases) and specificity (correct identification of control subjects) for macimorelin was summarized for age, gender, BMI and estrogen status subgroups containing n &gt; 10.
At least 8 of the 10 newly enrolled AGHD patients should have been correctly classified for a protocol pre-specified threshold of Peak GH concentration which was 8.5 (ng/ml).
Software CART Version 6.0 was used.</description>
          <population>PPS = per protocol set. Decision tree for sex abandoned. Following Amendment No. 4, no comparison with L-ARG + GHRH was performed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Misclassification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="11.2"/>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0"/>
                    <measurement group_id="O2" value="92.0"/>
                    <measurement group_id="O3" value="90.0"/>
                    <measurement group_id="O4" value="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="85.4"/>
                    <measurement group_id="O3" value="89.6"/>
                    <measurement group_id="O4" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug Related Adverse Events (AEs)</title>
        <description>Total number of participants with drug related AEs, following macimorelin administration of L-Arginine (ARG) - Growth Hormone Releasing Hormone (GHRH) administration.</description>
        <time_frame>14 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>AGHD Patients (=Cases)</title>
            <description>All AGHD patients who were enrolled in this study.</description>
          </group>
          <group group_id="O2">
            <title>Match Control (= Control)</title>
            <description>All matched control subjects who were enrolled in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Related Adverse Events (AEs)</title>
          <description>Total number of participants with drug related AEs, following macimorelin administration of L-Arginine (ARG) - Growth Hormone Releasing Hormone (GHRH) administration.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>following AEZS-130 administration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>following L-ARG+GHRH administration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days (time window between test visit (V2) and end-of-trial visit (V3)</time_frame>
      <desc>Only adverse events that occurred after the first dose of study drug (referred to as treatment-emergent adverse events (TEAEs)) were considered in the safety analysis. All treatment-emergent adverse events were summarized in terms of number and percentage of subjects and number and percentage of events within each treatment period by MedDRA system organ class and preferred term. A TEAE was attributed to the treatment that the subject received prior to the adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>AEZS-130: Cases</title>
          <description>All AGHD patients (cases) who received AEZS-130 (macimorelin).</description>
        </group>
        <group group_id="E2">
          <title>AEZS-130: Controls</title>
          <description>All matched control subjects who received AEZS-130 (macimorelin).</description>
        </group>
        <group group_id="E3">
          <title>L-ARG+GHRH: Cases</title>
          <description>All AGHD patients (cases) who received L-ARG+GHRH.</description>
        </group>
        <group group_id="E4">
          <title>L-ARG+GHRH: Controls</title>
          <description>All matched control subjects who received L-ARG+GHRH.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ECG T wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinits</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ECG T wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ECG change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study Protocol Section 10.7 Draft versions of abstracts or manuscripts must be made available to the co-authors and to the sponsor before any presentation of results or submission for publication. At least 2 weeks should be allowed for review and comment of an abstract and 4 weeks in the case of a full paper, respectively.
Multiple review cycles are usual for full papers and respective planning must account for this.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicola Ammer</name_or_title>
      <organization>Aeterna Zentaris</organization>
      <phone>+496942602 ext 3472</phone>
      <email>nammer@aezsinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

